- Spruce Biosciences (NASDAQ:SPRB) announced a $50M private placement to support the development of its lead enzyme replacement therapy, tralesinidase alfa, for Sanfilippo Syndrome Type B.
- The funding is intended to carry the program through a Biologics License Application submission in
Spruce Biosciences raises $50M in private placement; shares down (NASDAQ:SPRB)
By Press Room
